What Avego Management does

Avego Management, LLC is a private healthcare-dedicated investment firm founded in 2015 and headquartered in New York, with an additional office in Alpharetta, Georgia. The firm operates three distinct sub-branded strategies: Avego Healthcare Capital, which provides growth capital and operational partnership to commercial-stage healthcare companies across therapeutics, medical products, and services; Avego BioScience Capital, a venture strategy focused on mid-to-late stage financings for biotech companies developing therapeutics in oncology, neurology, immunology, ophthalmology, and rare disease; and Velan Capital, a public equities strategy employing a high-conviction long/short approach in healthcare. Avego's core proposition is its team of former healthcare entrepreneurs, operators, and finance professionals — most notably founders who previously built and sold Vidara Therapeutics (to Horizon Pharma in 2014) and Alaven Pharmaceutical (to Meda Pharma in 2010) — combined with a proprietary evidence-based scientific and medical diligence framework.

The firm's business model is that of an alternative asset manager: it deploys capital across private equity, venture, and public equities, earning revenue through management fees on committed/invested capital and carried interest on realized gains. Avego co-invests its own capital alongside limited partners to ensure alignment, and the firm distributes its offerings through direct outreach to healthcare entrepreneurs and management teams sourced via industry network referrals rather than traditional marketing. Between 2020 and early 2026, Avego made documented investments in at least 20 portfolio companies — including AtomVie Global Radiopharma (which it spun out in 2022), MapLight Therapeutics ($372.5M Series D in 2025), Alentis Therapeutics, Alveus Therapeutics, Caribou Biosciences, CellCentric, Jasper Therapeutics (via SPAC), and PBS Biotech — typically participating alongside tier-one healthcare investors such as RA Capital, Forbion, OrbiMed, GV, Johnson & Johnson Innovation, and Goldman Sachs Alternatives. Portfolio companies span specialty pharmaceuticals, biotech therapeutics, CDMO services, digital pharmacy, and veterinary diagnostics. The firm has 11–50 employees and is led by Founder and Managing Partner Bala Venkataraman, Managing Partner Thomas Vandervort, Partners Vishal Kapoor and Adam Morgan (CIO of Velan Capital), Managing Director Eric Pham PhD, and CFO/CCO Alyssa Romano.

Name

Avego Management

Legal name

Avego Management, LLC

Website

https://avego.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Avego Management is a private healthcare investment firm founded in 2015 that deploys capital across commercial-stage private equity, mid-to-late stage biotech venture, and public equities via three sub-brands (Avego Healthcare Capital, Avego BioScience Capital, Velan Capital), serving entrepreneurs and management teams building healthcare companies.

Ownership category

akta.pro rank

Product category

Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare private equity
• Biotech venture capital
• Healthcare investment management
• Specialty pharma investing
• Public healthcare equities

Headquarters

HQ city

Alpharetta

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Fund Management: Avego generates revenue through management fees and carried interest from its investment funds, including Avego Healthcare Capital (private equity), Avego BioScience Capital (venture), and Velan Capital (public equities).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Avego Management is a healthcare-focused investment firm that deploys capital across three strategies: Avego Healthcare Capital (private equity for commercial-stage healthcare companies), Avego BioScience Capital (venture capital for mid-to-late stage biotech companies), and Velan Capital (long/short public healthcare equities). The firm partners with healthcare entrepreneurs and management teams by providing growth capital, operational expertise, scientific diligence, and corporate development support to companies developing therapeutics, medical products, and healthcare services.

Product overview

Avego Management is a healthcare investment firm offering three distinct investment strategies: Avego Healthcare Capital (private equity for commercial-stage healthcare companies), Avego BioScience Capital (venture capital for mid-to-late stage biotech companies), and Velan Capital (public equities with long/short approach). These strategies operate as separate sub-brands under the unified Avego umbrella, providing capital and operational support across different stages and segments of the healthcare sector.

Differentiator

Problem solved

Functional benefit

Products and services

• Avego Healthcare Capital Private equity investment strategy providing growth capital and operational partnership to commercial-stage healthcare companies across therapeutics, medical products, and services in the U.S. and globally. Targets entrepreneurs and management teams building companies serving patients, physicians, and life science customers.
• Avego BioScience Capital Venture capital strategy partnering with biotech companies at pivotal stages of drug development. Provides mid-to-late stage venture financings to companies developing therapeutics using biologics, small molecules, cell & gene therapy modalities.
• Velan Capital Long/short public equities strategy focused on publicly traded healthcare companies. Targets superior risk-adjusted returns through deep sector expertise, undervalued assets, and high-quality management teams in specialty pharma and broader healthcare.

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• RA Capital Management: Healthcare-dedicated crossover fund investing across public and private biotech and pharma. Directly comparable to Avego's three-strategy healthcare platform (PE, venture, public equities) and frequently co-invests in the same rounds as Avego (CellCentric, Evommune, Escient).
• Baker Bros. Advisors: Healthcare-focused long/short public equity and venture investor. Closely parallels Velan Capital's public-equity strategy and Avego BioScience Capital's biotech venture strategy under one firm.
• Signet Healthcare Partners: Healthcare-focused PE/VC investing growth equity and venture in pharma products, services, and medical devices. Direct competitor to Avego Healthcare Capital and Avego BioScience Capital; an alumnus (Jerry Liao) moved from Signet to Avego.
• New Rhein Healthcare Investors: Healthcare-only growth equity and venture firm. Direct competitor to Avego's biotech and commercial-stage healthcare strategies; led the Alveus Therapeutics Series A in which Avego participated.
• Perceptive Advisors: Healthcare-focused investment manager combining public-equity hedge fund strategies with private venture and royalty investing. Closely mirrors Avego's three-strategy healthcare platform.
• BroadOak Capital Partners: Life-sciences-focused investment bank and investor providing growth capital and advisory. Direct co-investor with Avego in PBS Biotech and a comparable healthcare PE/VC firm.
• Logos Capital: Healthcare-focused fundamental long/short public equity fund. Closely parallel to Velan Capital's public-equities strategy and a comparable emerging healthcare investment firm.

Broad incumbents

• OrbiMed: Largest healthcare-dedicated investment firm globally, spanning private equity, venture, and public equities. Avego competes for the same biotech mandates and frequently co-invests (Alentis Therapeutics).

Regional players

• Forbion: European healthcare-dedicated venture and growth investor. Comparable biotech venture focus to Avego BioScience Capital; co-leads rounds Avego participates in (MapLight, CellCentric).
• Andera Partners: European life-sciences venture and growth investor. Comparable biotech venture focus to Avego BioScience Capital; co-leads rounds Avego participates in (Alveus Therapeutics).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avego Management